---
title: "TY PHAR. has repurchased 2.48% of its shares, costing 93.9418 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230288017.md"
description: "According to the Zhitong Finance APP, TY PHAR. announced that as of February 28, 2025, the company repurchased 12.7296 million shares through centralized bidding, accounting for 2.48% of the company's current total share capital, with a total payment of RMB 93.9418 million (excluding related transaction fees)"
datetime: "2025-03-03T08:56:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230288017.md)
  - [en](https://longbridge.com/en/news/230288017.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230288017.md)
generator: "portal-rs"
---

# TY PHAR. has repurchased 2.48% of its shares, costing 93.9418 million yuan

According to the Zhitong Finance APP, TY PHAR. (002728.SZ) announced that as of February 28, 2025, the company repurchased 12.7296 million shares through centralized bidding, accounting for 2.48% of the company's current total share capital, with a total payment of RMB 93.9418 million (excluding related transaction fees)

### Related Stocks

- [002728.CN](https://longbridge.com/en/quote/002728.CN.md)

## Related News & Research

- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [Lenzing shareholders approve EUR 300 million capital increase at extraordinary meeting](https://longbridge.com/en/news/296902548.md)
- [Qlife enters fully funded feasibility deal with global pharma company for Egoo Health biomarker application](https://longbridge.com/en/news/296995766.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)
- [A: Q3 results exceeded expectations with strong growth in pharma, CDMO, and China, driving raised FY26 guidance](https://longbridge.com/en/news/297095880.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**